Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up

Written by Sharon Salt, Editor

This week, we’re covering some of the latest industry headlines on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s disease and cannabidiol oral solution for seizures. Discover more about our selection of this week’s highlights below: Cannabinoid-derived drug (Epidyolex™) gains positive CHMP opinion for seizures Ponesimod hits key endpoints for Phase III trial in adults with relapsing multiple sclerosis Accordion Pill® fails to achieve statistical superiority to Sinemet® for Parkinson’s disease Cannabinoid-derived drug (Epidyolex™) gains positive CHMP opinion for seizures GW Pharmaceuticals (CA, USA) has received a positive opinion for Epidyolex™ (cannabidiol) for its use as an adjunctive...

To view the full article, please register now for access

It's completely free